IDYA IDEAYA Biosciences
- 31.280
- +1.290+4.30%
- 31.280
- 0.0000.00%
IDEAYA Biosciences News
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $64
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
IDEAYA Biosciences Analyst Ratings
BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Promising Developments and Strong Financial Position Drive IDEAYA Biosciences Buy Rating
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
Oppenheimer Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $53
IDEAYA Biosciences Price Target Maintained With a $53.00/Share by Oppenheimer
IDEAYA Biosciences Analyst Ratings
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $66
Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
Capital One Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Promising Clinical Data and Strong Safety Profile Support Buy Rating for IDEAYA Biosciences
IDEAYA Biosciences Analyst Ratings
UBS Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $50
Analysis
Price Target
No Data
No Data